Show simple item record

dc.contributor.authorGlendenning, JL
dc.contributor.authorBarbachano, Y
dc.contributor.authorNorman, AR
dc.contributor.authorDearnaley, DP
dc.contributor.authorHorwich, A
dc.contributor.authorHuddart, RA
dc.date.accessioned2018-07-25T11:02:39Z
dc.date.issued2010-05
dc.identifier.citationCancer, 2010, 116 (10), pp. 2322 - 2331
dc.identifier.issn0008-543X
dc.identifier.urihttps://repository.icr.ac.uk/handle/internal/2135
dc.identifier.eissn1097-0142
dc.identifier.doi10.1002/cncr.24981
dc.description.abstractBackground Testicular cancer is curable in the majority of men, and persisting treatment toxicity is a concern. The authors report a cross-sectional study of the long-term effects of chemotherapy (C) on neurologic function and development of Raynaud phenomenon.Methods Seven hundred thirty-nine patients who were treated between 1982 and 1992 gave consent to enter the study. Patients were classified according to the receipt of C (n = 384) or no C (n = 355). Patients completed a general health questionnaire and a quality-of-life form (the European Organization for Research and Treatment of Cancer Quality-of-Life C30 questionnaire with testicular module). Symptom scores of 3 or 4 were considered clinically significant. Patients were assessed in the clinic, and clinical history was used to diagnose Raynaud phenomenon (RP) and tinnitus. Examinations included peripheral nerve function testing for light touch and vibration sense. Five hundred seventy-seven patients underwent audiometry.Results On physician assessment, peripheral neuropathy and RP were more common after C (21.7% vs 9.1% [P<.001] and 20.3% vs 1.7% [P<.001], respectively). Similar results were obtained for symptom scores (12.5% vs 5.5% [P = .002] and 9.7% vs 3.7% [P<.001], respectively). On multivariate analysis, for peripheral neuropathy, the significant predictors were cisplatin dose, carboplatin dose, and age. For RP, the significant predictor was bleomycin. Significant differences in hearing thresholds were noted at 8000 hertz only and, on multivariate analysis, were related to age, cisplatin dose, and vincristine dose. Auditory symptom scores did not differ between groups.Conclusions With long-term follow-up, peripheral neuropathy and RP remained detectable in approximately 20% of patients and caused significant symptoms in 10% of patients. Detectable effects on high frequency remained but caused little symptomatic problem. These effects persisted and were related to the cumulative chemotherapy dose.
dc.formatPrint
dc.format.extent2322 - 2331
dc.languageeng
dc.language.isoeng
dc.subjectMicrocirculation
dc.subjectHumans
dc.subjectTesticular Neoplasms
dc.subjectHearing Loss
dc.subjectTinnitus
dc.subjectPeripheral Nervous System Diseases
dc.subjectRaynaud Disease
dc.subjectAntineoplastic Combined Chemotherapy Protocols
dc.subjectTime
dc.subjectAdolescent
dc.subjectAdult
dc.subjectAged
dc.subjectMiddle Aged
dc.subjectMale
dc.titleLong-term neurologic and peripheral vascular toxicity after chemotherapy treatment of testicular cancer.
dc.typeJournal Article
rioxxterms.versionofrecord10.1002/cncr.24981
rioxxterms.licenseref.startdate2010-05
rioxxterms.typeJournal Article/Review
dc.relation.isPartOfCancer
pubs.issue10
pubs.notesNot known
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.organisational-group/ICR
pubs.organisational-group/ICR/Primary Group
pubs.organisational-group/ICR/Primary Group/ICR Divisions
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Closed research teams/Clinical Academic Radiotherapy (Dearnaley)
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging
pubs.organisational-group/ICR/Primary Group/ICR Divisions/Radiotherapy and Imaging/Clinical Academic Radiotherapy (Huddart)
pubs.publication-statusPublished
pubs.volume116
pubs.embargo.termsNot known
icr.researchteamClinical Academic Radiotherapy (Dearnaley)en_US
icr.researchteamClinical Academic Radiotherapy (Huddart)en_US
dc.contributor.icrauthorHorwich, Alanen
dc.contributor.icrauthorDearnaley, Daviden
dc.contributor.icrauthorHuddart, Roberten


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following collection(s)

Show simple item record